LACTEL 75:25 DL-PLG (B6007-2) is introduced as the matrix-forming component in solvent-extraction microencapsulation lines for extended-release injectables. The polymer phase is prepared at 15–30% w/w in dichloromethane, and the drug:polymer mass ratio is held between 1:5 and 1:20 depending on whether the payload is a hydrophobic small molecule, a peptide, or a low-dose conventional cytotoxic. In a validated 50–200 L jacketed glass reactor, a 2–5% w/v aqueous poly(vinyl alcohol) continuous phase is maintained at 2–8°C to limit primary emulsion coalescence. The primary W/O emulsion is generated in an in-line rotor-stator disperser operating at 8,000–15,000 rpm, and the resulting W/O/W double emulsion is transferred under vacuum at 300–450 mbar with a 35–40°C jacket temperature ramp. Residual dichloromethane is reduced below the ICH Q3C Option 2 limit of 600 ppm, and residual PVA is controlled below 0.5% w/w by repeated water washes and cross-flow filtration. Sterility is confirmed by USP <71>, bacterial endotoxin by USP <85>, subvisible particle counts by USP <788> and USP <787>, in vitro release by USP <711> Apparatus 4 in 0.05 M phosphate-buffered saline pH 7.4 at 37°C, and polymer identity by gel permeation chromatography with refractive index detection and 1H-NMR. Terminal product categories include leuprolide acetate-type depot powders, exenatide-loaded microspheres filled into dual-chamber syringes, and sterile lyophilized microsphere formulations for intramuscular administration. Pre-drying of the polymer is mandatory when ambient RH exceeds 60%, and the lyophilized cake is stored below -20°C with residual moisture held within 1.0–1.5% because higher moisture accelerates autocatalytic hydrolysis of the 75:25 DL-lactide:glycolide backbone.

How Does Solvent Exchange Rate Control Burst Release in a 75:25 DL-PLG Depot?

For in-situ forming depots, B6007-2 is dissolved in N-methyl-2-pyrrolidone at 25–40% w/w, with drug loading typically 3–10% w/w of the final liquid formulation. Below 25% w/w polymer, the depot spreads along subcutaneous tissue planes before precipitation; above 45% w/w, the formulation becomes difficult to expel through a 21–23G needle at hand pressure. The solvent exchange process, not simple polymer degradation, governs release during the first 72 h, because NMP efflux into the interstitial space and water influx into the polymer-rich phase determine the coagulation rate and internal porosity of the depot. Production-scale batches are compounded in a planetary mixer under dry nitrogen at 25°C for 3–5 h, followed by vacuum degassing at 50–100 mbar to remove dissolved oxygen and prevent oxidation-induced molecular-weight shifts. In-process viscosity is measured by rotational viscometry, and values above 1,000 mPa·s are rejected because they correlate with needle clogging during 21G injection. In-line pre-filtration through 250 μm mesh removes agglomerates; sterile filtration through 0.2 μm membranes is not feasible for 25–40% w/w polymer solutions, so aseptic filling is required. The finished solution is aseptically filled into pre-filled syringes with Luer-lock closures. Terminal product types include leuprolide acetate in-situ depots, periodontal antibiotic depots, and veterinary growth-promoting peptide injectables. Compliance requirements include ISO 10993-1:2018 biological evaluation, ISO 13485:2016 clause 7.5.2 for process validation, USP <85> for endotoxin, and ICH Q3C for residual NMP class 2 solvent control using the permitted daily exposure of 5.3 mg/day as the derivation basis. Gamma irradiation at 15–25 kGy may reduce number-average molecular weight by 30–50%; steam sterilization is incompatible because hydrolytic cleavage initiates at moist heat above 60°C. Polymer pre-drying at 30°C under 0.1 mbar for 24 h is mandatory when ambient RH exceeds 60%.

Solvent Evaporation Parameters for Sub-300 nm PLGA Nanoparticle Formation

Sub-300 nm nanoparticle formation with B6007-2 requires polymer concentration in the organic phase between 0.5% w/v and 2% w/v in acetone or ethyl acetate, with an aqueous antisolvent containing 0.1–0.5% w/v poloxamer 188 or polysorbate 80. The drug:polymer mass ratio is typically held between 1:5 and 1:20 for hydrophobic small molecules; higher drug loading beyond 1:5 widens the polydispersity index above 0.2 because precipitation becomes uncontrolled. In a confined impingement mixer or T-junction, the organic phase is first passed through a 0.2 μm PTFE membrane, and the organic:aqueous volumetric ratio is maintained between 1:5 and 1:10 at total flow rates of 10–100 mL/min. Solvent removal is carried out by rotary evaporation at 30°C and 150–250 mbar, followed by tangential flow filtration through a 100 kDa MWCO membrane to remove free drug and surfactant. Lyophilization uses mannitol or trehalose as cryoprotectant at 5–15% w/v; the final cake is stored below -20°C and must be re-constituted with 0.9% w/v sodium chloride before administration. Mean particle diameter and polydispersity are determined by dynamic light scattering in accordance with ISO 22412:2017, and zeta potential is measured by electrophoretic light scattering using ISO 13099-1:2012, with acceptable values between -15 mV and -35 mV. Terminal product types include lyophilized nanoparticle vials for intravenous oncology therapy, peritoneal or pulmonary administration, and sterile nanoparticle combinations for central nervous system delivery. Compliance requirements include ISO 10993-5 for cytotoxicity, USP <788> and USP <787> for subvisible particulates, USP <85> for endotoxin, and ICH Q3C residual solvent limits for acetone and ethyl acetate at 5000 ppm as Class 3 solvents. Acetone may be used instead of dichloromethane to avoid the Class 2 solvent residual limit; however, polymer solubility in acetone is lower, requiring the organic phase to be held at 35–40°C to prevent gel-phase formation.

Porous Scaffold Architecture and Solvent-Leaching Compression Moulding with 75:25 DL-PLG

For bone-void and guided tissue regeneration scaffolds, B6007-2 is processed by solvent casting with 10–15% w/v in chloroform and particulate leaching using sieved NaCl porogen of 100–250 μm at polymer:porogen mass ratios of 1:5 to 1:10. The slurry is cast into PTFE-coated aluminium moulds and dried at 25°C for 24 h, then compression moulded at 60–80°C and 5–10 MPa, followed by porogen leaching in deionised water for 48 h. The resulting architecture has interconnected porosity between 80% and 90%, which is verified by micro-computed tomography and gravimetric analysis; pore size distribution is confirmed by mercury intrusion porosimetry in accordance with ISO 15901-1:2016. Mechanical compression testing is performed according to ASTM D695-15 or ISO 604:2002, with modulus values in the 10–30 MPa range depending on porogen volume fraction. Terminal product categories include patient-specific bone scaffolds shaped by CNC milling, dental ridge preservation plugs, and cartilage repair matrices. Compliance requirements include ISO 10993-5 for cytotoxicity, ISO 10993-10 for sensitization, ISO 10993-12 for sample preparation, and ISO 13485:2016 for cleanroom manufacturing. Residual chloroform must be reduced below the ICH Q3C Class 2 limit of 60 ppm, and terminal sterilization is performed with gamma irradiation at 10–15 kGy or ethylene oxide, with aeration time calculated to reduce ethylene oxide residues below 4 mg/day per ISO 10993-7. Because solvent-leached scaffolds are hygroscopic, post-sterilization packaging must maintain internal humidity below 30% RH to prevent plasticization and pore collapse during shelf storage.

In the 1–20 μm aerodynamic diameter band, B6007-2 is used as an antigen delivery matrix for intramuscular and subcutaneous single-injection vaccine formulations. The polymer is dissolved at 20–30% w/w in ethyl acetate and combined with an aqueous antigen phase at a polymer:antigen mass ratio from 10:1 to 50:1, with 0.5–2% w/v trehalose as lyoprotectant. Membrane emulsification through a 5 μm pore-size shirasu porous glass membrane at 0.5–2 bar provides a narrower size distribution than rotor-stator homogenization, but the primary emulsion temperature must be held below 8°C to prevent antigen denaturation at the solvent interface. Solvent evaporation is carried out at 37°C and 300 mbar, and the microparticles are optionally spray dried at inlet 80°C and outlet 45°C to reduce residual moisture. Terminal product forms include lyophilized vaccine microparticles with alum-free adjuvant effect, dual-adjuvant combinations with 1–20 μm particle-size targeting for antigen-presenting cell uptake, and subcutaneous immune-priming injections with reduced dosing frequency. Compliance requirements include USP <788>, USP <85>, ISO 10993-10 for sensitization, and WHO Technical Report Series guidance for vaccine adjuvant characterization. Because published data for B6007-2 specifically in membrane-emulsified antigen microparticles is limited, formulation ranges are benchmarked from PLGA 75:25 matrices with similar inherent viscosity; each antigen-polymer combination requires verification of antigen integrity by enzyme-linked immunosorbent assay after extraction and particle-size distribution by laser diffraction using ISO 13320:2020.

When Ethyl Acetate Replaces Dichloromethane in Ophthalmic Implant Melt Extrusion

Ophthalmic intravitreal rods with B6007-2 are produced by melt extrusion rather than solvent casting when low residual solvent is required for vitreous cavity use. The polymer and corticosteroid are dry-blended at drug:polymer mass ratios of 1:1 to 1:9, with triethyl citrate plasticizer at 0–5% w/w, and extruded through a co-rotating twin-screw extruder with 20:1 L/D ratio, barrel temperature profile 70–100°C, die temperature 90–105°C, and screw speed 50–100 rpm under nitrogen purge. The extrudate is pelletized to 0.5–1.5 mm diameter strands, then loaded into 22G or 25G applicator systems under aseptic conditions. Terminal product types include extended-release corticosteroid intravitreal implants, anti-inflammatory rods for postoperative uveitis, and combination devices for sustained retinal drug delivery. Compliance requirements include ISO 10993-1:2018, ISO 10993-4 for blood compatibility, USP <789> for ophthalmic particulates, USP <85>, and ICH Q3C residual solvent limits for ethyl acetate at 5000 ppm. Melt residence time above 5 min accelerates hydrolytic chain scission and shifts the release profile toward faster diffusion; therefore, the extruder barrel is cooled at the feed zone to 60–70°C and the die is validated by in-process melt pressure below 50 bar. Steam sterilization is incompatible, while gamma irradiation at 15–25 kGy is acceptable only if molecular-weight loss is confirmed by gel permeation chromatography before release. Pre-extrusion drying at 30°C under 0.1 mbar for 24 h is required, with Karl Fischer titration confirming moisture below 0.5% before charging the hopper.